USPTO Examiner KWON JOHN SEUNGJAI - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18745572Dry Powdered Compositions and Methods and Uses ThereofJune 2024March 2025Allow900YesNo
18608090PYRAZOLE DERIVATIVE AND HARMFUL ORGANISM-CONTROLLING AGENTMarch 2024October 2024Allow700NoNo
18054767SUSTAINED RELEASE DELIVERY SYSTEMS COMPRISING TRACELESS LINKERSNovember 2022May 2025Allow3000NoNo
17815485GRAPHENE BIOSCAFFOLDS AND THEIR USE IN CELLULAR THERAPYJuly 2022January 2025Abandon2930NoNo
17758877GAS-GENERATING MICELLE FOR REDUCING LOCALIZED FATJuly 2022May 2024Allow2220NoNo
17757245FULVESTRANT PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOFJune 2022April 2025Allow3410NoNo
17804204INJECTABLE FORMULATIONS OF APREPITANTMay 2022November 2024Abandon2920NoNo
17722490STATIC-PROOF WATER-BASED PROTECTIVE FILM AND PREPARATION METHOD THEREOFApril 2022March 2024Abandon2310NoNo
17720440PROTECTIVE FILM WITH ANTIBACTERIAL PROPERTY, METHOD FOR PREPARING THE SAME, AND PRODUCT HAVING THE SAMEApril 2022March 2024Abandon2310NoNo
17707969HIGHLY COMPRESSIBLE SHAPE MEMORY DOUBLE NETWORK HYDROGEL, USE AND PREPARATION METHOD THEREOF, AND INTERVERTEBRAL DISK SCAFFOLDMarch 2022November 2024Abandon3230NoNo
17693271PROCESS FOR PRODUCING AN ANDROGRAPHOLIDE CARRIER SYSTEMMarch 2022June 2024Allow2800NoNo
17690084CANNABINOID-CONTAINING SKIN CARE COMPOSITIONSMarch 2022December 2023Abandon2110NoNo
17690794HYDROXYQUINOLINE COMPOUNDS AND METHODS OF USE AS PIGMENT MODIFYING AGENTSMarch 2022March 2025Allow3631NoNo
17689457MICROEMULSION MIXTURE AND METHOD OF USING THE SAME, AND PHARMACEUTICAL MICROEMULSION MIXTURE AND METHOD OF USING THE SAMEMarch 2022August 2023Allow1710NoNo
17674598PREPARATION OF SOLUBLE FORM OF CURCUMINFebruary 2022December 2023Allow2210YesNo
17592656NOVEL CRYSTALLINE FORM OF PYROXASULFONE, METHODS FOR ITS PREPARATION AND USE OF THE SAMEFebruary 2022December 2023Abandon2310NoNo
17626043CANCER CELL-TARGETED DRUG DELIVERY CARRIER AND COMPOSITION FOR PROMOTING PHOTO-THERMAL TREATMENT EFFECTS, BOTH OF WHICH CONTAIN M1 MACROPHAGES AS ACTIVE INGREDIENTJanuary 2022April 2025Allow3910NoNo
17624836A METHOD FOR THE PREPARATION OF A GEL-FORMING COMPOSITIONJanuary 2022April 2025Abandon3940YesNo
17623805COMPOSITIONS AND METHODS FOR TREATING MYOCARDIUM WITH MESENCHYMAL STEM CELL SCAFFOLDDecember 2021June 2025Abandon4210NoNo
17620824GASTRORETENTIVE DOSAGE FORMS OF LEVODOPA AND CARBIDOPADecember 2021May 2025Abandon4110NoNo
17620327LIPOSOMAL DOXORUBICIN FORMULATION, METHOD FOR PRODUCING A LIPOSOMAL DOXORUBICIN FORMULATION AND USE OF A LIPOSOMAL DOXORUBICIN FORMULATION AS A MEDICAMENTDecember 2021May 2025Allow4020NoNo
17644169MOISTURIZING COMPOSITION AND METHODDecember 2021October 2024Abandon3430YesNo
17551062Long Chain Fatty Acid Compound Colloidal Sulfur Formulations Comprising Functional Ingredients For Acne Treatment And Other ApplicationDecember 2021March 2025Abandon3910NoNo
17617134COMPOSITIONS AND METHODS FOR IMPROVING WELLNESSDecember 2021March 2025Abandon4010NoNo
17616992THERMOGELLING CANNABINOID COMPOSITION AND METHOD OF MANUFACTURE AND USE THEREOFDecember 2021February 2025Abandon3810NoNo
176157861-PHENYL-5-AZINYLPYRAZOLYL-3-OXYALKYL ACIDS AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTHDecember 2021August 2024Allow3200NoNo
17614635PHARMACEUTICAL COMPOSITION FOR PROMOTING OSTEOGENESIS, COMPRISING OSTEOBLAST-DERIVED MITOCHONDRIANovember 2021March 2025Allow3920YesNo
17610962COMPOSITIONS COMPRISING LOPINAVIR AND TREATMENT OF CONDITIONSNovember 2021May 2025Allow4211NoNo
17609384MONODISPERSE EMULSIONS TEMPLATED BY THREE-DIMENSIONAL STRUCTURED MICROPARTICLES AND METHODS OF MAKING THE SAMENovember 2021April 2025Abandon4220NoNo
17518896Disinfecting Composition and Related MethodsNovember 2021October 2023Abandon2310NoNo
17519413METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASESNovember 2021January 2025Abandon3820NoYes
17606008GENE EXPRESSION PROMOTER FOR SKIN BEAUTIFICATIONOctober 2021February 2025Abandon4010NoNo
17604592MICROCAPSULES CONTAINING CURCUMIN, AND METHODS FOR THE PRODUCTION THEREOFOctober 2021January 2025Abandon3901NoNo
17603816INJECTABLE TRIAMCINOLONE FORMULATIONSOctober 2021May 2025Allow4330YesNo
17476789Hair Loss Treatment CompositionSeptember 2021February 2024Abandon2920NoNo
17436354Edible Film Comprising Adjacent Conjoined StripsSeptember 2021January 2024Abandon2810NoNo
17434990NUTRACEUTICAL COMPOSITIONSAugust 2021December 2024Abandon4010NoNo
17412442CANNABINOID AND MENTHOL TRANSDERMAL DELIVERY SYSTEMS AND METHODSAugust 2021August 2024Allow3630NoNo
17428843COMPOSITIONS AND METHODS FOR INHIBITING POST-SURGICAL ADHESIONSAugust 2021August 2024Allow3710NoNo
17381613CANNABINOID STORAGE STABILITYJuly 2021May 2024Abandon3420NoNo
17419183BIOBASED THICKENING COMPOSITION COMPRISING A POLY(FARNESENE)June 2021August 2024Allow3810NoNo
17419102LIQUID COMPOSITIONSJune 2021May 2024Abandon3420NoNo
17335039Injectable Temperature-sensitive Composite Hydrogel Containing Adipose-derived Mesenchymal Stem Cells and Preparation Method and Application ThereofMay 2021October 2023Abandon2810NoNo
17293495ATTRACTANT COMPOSITION FOR THE SPECIES DELOTTOCOCCUS ABERIAE, METHODS FOR THE MONITORING, DETECTION AND/OR CONTROL OF THE PESTMay 2021August 2024Allow3910NoNo
17292225COMPOSITION FOR STERILIZATION AND CLEANING, METHOD FOR PRODUCING SAME, AND STERILIZATION AND CLEANING METHOD EMPLOYING SAMEMay 2021March 2025Allow4621YesNo
17290942MANAGEMENT OF RISK OF CATION OVERLOAD AND ELECTROLYTE IMBALANCE WITH TOPICALLY APPLIED BUFFERSMay 2021November 2023Abandon3010NoNo
17246883COMPOSITION AND PROCESS FOR RECONDITIONING RESPIRATORS AND OTHER PERSONAL PROTECTIVE EQUIPMENTMay 2021October 2023Abandon2910NoNo
17240919Dry Powdered Compositions and Methods and Uses ThereofApril 2021February 2024Allow3320NoNo
17286181HEMOSTATIC MATERIALApril 2021July 2025Abandon5131YesNo
17222026Devices and Methods for Nerve RegenerationApril 2021August 2023Allow2810NoNo
17282121HYDROGEL COMPOSITIONSApril 2021November 2023Abandon3110NoNo
17282069PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODSApril 2021November 2024Abandon4410NoNo
17277423HIGH-PURITY PEG LIPIDS AND USES THEREOFMarch 2021April 2025Allow4931NoNo
17204106MEDICATED CANNABINOID COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENTMarch 2021October 2023Abandon3110NoNo
17276568Medical Use of HonokiolMarch 2021February 2025Abandon4720NoNo
17270160NanoparticlesFebruary 2021October 2023Allow3200NoNo
17170310COMPOSITIONS AND METHODS FOR TARGETING ANGIOGENESIS FOR FRACTURE NONUNION TREATMENT UNDER INFLAMMATORY DISEASESFebruary 2021June 2025Abandon5240YesNo
17263342SYNERGISTICALLY EFFECTIVE HERBICIDE COMPOSITION COMPRISING PYRIDATE AND AT LEAST ONE DEFINED 4-HPPD INHIBITORJanuary 2021April 2025Allow5130NoNo
17158583COLON LAVAGE SYSTEMJanuary 2021January 2024Allow3510YesNo
17262300SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A THERAPEUTIC AGENT FOR TREATING DEMENTIA AND USES THEREOFJanuary 2021October 2024Allow4520NoNo
17262142A NANOPARTICLE FOR RADIATION PROTECTIONJanuary 2021August 2024Abandon4310NoNo
17261323PROTEIN ENCAPSULATION OF NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONSJanuary 2021May 2025Abandon5230NoNo
17257918REGENERATION OF TENDON AND TENDON SHEATH, RESTORATION MATERIAL, AND USE OF RESTORATION MATERIALJanuary 2021October 2024Allow4620YesNo
17257973URACIL COMPOUND AND USE THEREOFJanuary 2021October 2023Allow3300NoNo
17135194OVERPOWERED ABA RECEPTOR AGONISTSDecember 2020July 2024Allow4311YesNo
17253731PESTICIDALLY ACTIVE ISOXAZOLINE DERIVATIVES CONTAINING AN AMIDE GROUP AND AN AZETIDINE SULFONE GROUPDecember 2020April 2024Abandon4010NoNo
17253165HERBICIDAL COMPOUNDSDecember 2020August 2023Allow3200YesNo
17058854WHEY PROTEIN CONCENTRATE IN ASSOCIATION WITH ANTITUMOUR TREATMENTNovember 2020April 2024Abandon4110NoNo
17250107PYRAZOLE DERIVATIVE AND HARMFUL ORGANISM-CONTROLLING AGENTNovember 2020December 2023Allow3701NoNo
17099077COMPOSITIONS AND METHODS FOR ADDRESSING VISION IMPAIRMENTNovember 2020December 2024Abandon4950YesNo
17080983NOVEL CLOTHIANIDIN COMPOSITIONS AND METHODS OF USE THEREOFOctober 2020May 2023Allow3010NoNo
16966278COMPOSITION FOR BONE GRAFTING, COMPRISING NUCLEIC ACIDS, BONE GRAFT MATERIAL AND CATIONIC POLYMER, AND BONE GRAFT KIT FOR MANUFACTURING SAMEOctober 2020June 2023Abandon3510NoNo
17046909OIL-BASED SUSPENSION CONCENTRATESOctober 2020December 2023Abandon3820NoNo
17046889SOLID FORMULATION OF INSECTICIDAL MIXTURESOctober 2020December 2024Allow5050YesNo
17046477SOLID FORMULATION OF INSECTICIDAL MIXTURESOctober 2020August 2024Allow4630YesNo
17045010INCREASING WATER RETENTION IN SOIL TO MITIGATE DROUGHTOctober 2020April 2025Allow5430YesNo
17040833FUNGICIDAL COMBINATIONSSeptember 2020October 2024Abandon4841YesNo
16992857TISSUE REPAIR MEMBRANE ADAPTED FOR ADHESION AND LUBRICATION, AND METHODS FOR PREPARING THE SAMEAugust 2020June 2025Allow5850YesNo
16966990HERBICIDAL MIXTURESAugust 2020October 2023Abandon3920NoNo
16960413ALGINATE ENCAPSULATION OF FUNGAL MICROSCLEROTIAJuly 2020August 2024Abandon4921NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KWON, JOHN SEUNGJAI.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
1
(100.0%)
Filing Benefit Percentile
0.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KWON, JOHN SEUNGJAI - Prosecution Strategy Guide

Executive Summary

Examiner KWON, JOHN SEUNGJAI works in Art Unit 1615 and has examined 78 patent applications in our dataset. With an allowance rate of 44.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner KWON, JOHN SEUNGJAI's allowance rate of 44.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KWON, JOHN SEUNGJAI receive 1.69 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KWON, JOHN SEUNGJAI is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +28.3% benefit to allowance rate for applications examined by KWON, JOHN SEUNGJAI. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.6% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.7% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Petition Practice

When applicants file petitions regarding this examiner's actions, 111.1% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.7% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.